British Columbia has become the first Canadian province to cover NovoCure’s Tumor Treating Fields (TTFields) therapy for newly diagnosed glioblastoma patients, removing a major reimbursement barrier in one of Canada’s largest health‑care markets.
The coverage decision follows Health Canada’s November 2022 approval of TTFields for glioblastoma and expands reimbursement to patients treated through BC Cancer, the province’s public oncology program. TTFields is already reimbursed in several countries, including Austria, Czechia, France, Germany, Israel, Japan, Spain, Sweden, Switzerland, and the United States.
NovoCure’s Q4 2024 financial results show net revenues of $161.3 million, a 21% year‑over‑year increase, and full‑year 2024 net revenues of $605.2 million, up 19% from the prior year. The company reported a net loss of $65.9 million for Q4 2024, with a gross margin of 79%. The new provincial coverage is expected to drive patient enrollment and revenue growth in Canada, complementing the company’s expanding global footprint.
Lamia Kalfane, Country Manager for NovoCure Canada, said, “The newly announced coverage in British Columbia for Tumor Treating Fields therapy means more patients will have access to a treatment option that may potentially extend their survival. We are deeply grateful for the partnership and collaboration of BC Cancer in achieving this milestone.”
Globally, over 40,000 patients have been treated with TTFields therapy, and the coverage in British Columbia positions NovoCure to increase its patient base in Canada, where the company already has 4,126 active patients worldwide.
The decision underscores NovoCure’s strategy to broaden access to its device‑based therapy across multiple indications and markets, potentially accelerating adoption and supporting the company’s broader multi‑indication pipeline.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.